Nilotinib, but not imatinib, increased intracellular doxorubicin in human STS cells.

<p>Synovial sarcoma SW982 and leiomyosarcoma SK-UT-1 cells were incubated with vehicle (DMSO) or DXR (1 µM) in the absence (vehicle, V) or presence of nilotinib (1–10 µM) or imatinib (1–10 µM) as described in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0037735#s2" target="_blank">Material and Methods</a> section. After 24 h incubation, intracellular DXR was measured by its fluorescence intensity with flow cytometry. <i>Left</i>, Median of intracellular DXR fluorescence in the absence (V) or presence of TK inhibitors normalized to vehicle-treated cells (taken as 100%). Each column represents mean ± SEM of seven independent experiments. <i>Right</i>, Representative flow cytometry analysis of the intracellular DXR fluorescence detected with excitation at 488 nm and emission at 580 nm in both cell lines. ^***<i>P</i><0.001 versus DXR-treated cells.